LIVE WEBINAR: Saturday, June 26, 2021, 8:00 AM – 3:00 PM Central Time (9:00 AM – 4:00 PM Eastern Time)

What Happened at ASCO and More: Investigators Review Recent Data Sets and Provide Perspectives on Current Oncology Care — A Daylong Multitumor Educational Webinar in Partnership with Texas Society of Clinical Oncology (TxSCO)

A CME-MOC/NCPD Accredited Virtual Event

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Saturday, June 26 for this daylong multitumor CME-MOC/NCPD-accredited live webinar
8:00 AM – 3:00 PM Central Time (9:00 AM – 4:00 PM Eastern Time)

Faculty

Faculty to be announced.

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


CME-MOC/NCPD-accredited LIVE Webinar
Saturday, June 26, 2021
8:00 AM – 3:00 PM Central Time (9:00 AM – 4:00 PM Eastern Time)

Lung Cancer | 8:00 AM – 9:00 AM CT (9:00 AM – 10:00 AM ET)

PART 1: TARGETED THERAPIES FOR NON-SMALL CELL LUNG CANCER (NSCLC)

Localized and Metastatic NSCLC with EGFR Mutations

  • Design, eligibility criteria and available efficacy and safety results from the Phase III ADAURA trial evaluating adjuvant osimertinib versus placebo for early-stage NSCLC with EGFR mutation after complete tumor resection
  • Recent FDA approval of adjuvant osimertinib; patient selection and optimal incorporation into clinical care
  • Optimal first-line treatment for metastatic NSCLC with EGFR tumor mutations; overall and progression-free survival benefit observed with up-front osimertinib
  • Incidence, clinical relevance and spectrum of resistance mechanisms in patients experiencing disease progression on osimertinib
  • Mechanism of action, available data and ongoing evaluation of the novel HER3-directed antibody-drug conjugate patritumab deruxtecan for metastatic EGFR tyrosine kinase inhibitor-resistant NSCLC
  • Available data with novel agents targeting EGFR exon 20 mutations; FDA breakthrough therapy designations and development plans for mobocertinib and amivantamab

Metastatic NSCLC with ALK and ROS1 Rearrangements

  • Optimal selection of first- and later-line therapy for patients with metastatic NSCLC with ALK rearrangements
  • Available data informing the use of alectinib, brigatinib and lorlatinib as first-line therapy for patients with NSCLC with ALK rearrangements
  • Key factors in the selection of therapy for patients with progressive NSCLC with ALK rearrangements; role of repeat biomarker testing and implications for decision-making
  • Principal findings demonstrating the efficacy and safety of entrectinib for NSCLC with a ROS1 rearrangement; appropriate integration of entrectinib into clinical practice
  • Intracranial response rates observed with entrectinib for patients with NSCLC with ROS1 rearrangements and CNS involvement; implications for therapy
  • Published data, ongoing trials and development plans for other “next-generation” ROS1 inhibitors (eg, repotrectinib, larotrectinib, lorlatinib, ceritinib)

Metastatic NSCLC with Genomic Aberrations Beyond EGFR, ALK and ROS1

  • Frequency of other targetable mutations (eg, RET, MET exon 14, HER2, KRAS) in metastatic NSCLC; optimal testing protocols
  • Reported clinical activity and safety data with selpercatinib and pralsetinib for patients with advanced NSCLC and RET alterations; integration into clinical practice
  • Published findings with and current clinical roles of capmatinib and tepotinib for patients with NSCLC with MET exon 14 mutations
  • Key efficacy and safety outcomes from the Phase II DESTINY-Lung01 study evaluating trastuzumab deruxtecan (T-DXd) for NSCLC with a HER2 mutation; FDA breakthrough therapy designation, ongoing evaluation and potential nonresearch role of T-DXd
  • Available safety and efficacy data with and ongoing evaluation of sotorasib for advanced NSCLC with a KRAS G12C mutation

PART II: IMMUNOTHERAPY AND OTHER NONTARGETED APPROACHES FOR PATIENTS WITH LUNG CANCER

Small Cell Lung Cancer (SCLC)

  • Key efficacy and safety findings with atezolizumab or durvalumab in combination with chemotherapy for patients with previously untreated extensive-stage SCLC
  • Appropriate integration of first-line carboplatin/etoposide/atezolizumab and platinum/etoposide/durvalumab into SCLC management
  • Other immune checkpoint inhibitor-based strategies under evaluation for patients with extensive- or limited-stage SCLC
  • Available and emerging data with and current clinical role of lurbinectedin for patients with SCLC and disease progression after prior platinum-based therapy
  • Efficacy and safety results from randomized studies evaluating trilaciclib as a means to preserve bone marrow function during chemotherapy in patients with extensive-stage SCLC; recent FDA approval and optimal incorporation into routine practice

Localized and Locally Advanced NSCLC

  • Available efficacy findings from the Phase III CheckMate 816 trial evaluating nivolumab in combination with chemotherapy as neoadjuvant therapy for patients with resectable NSCLC; implications for ongoing research and clinical practice
  • Design, eligibility criteria and primary and secondary endpoints of the Phase III IMpower010 trial evaluating atezolizumab versus best supportive care after adjuvant chemotherapy for patients with completely resected NSCLC
  • Emerging results from IMpower010 documenting a disease-free survival advantage with adjuvant atezolizumab; current and potential nonresearch role of adjuvant atezolizumab
  • Patient selection for and practical implementation of consolidation durvalumab after chemoradiation therapy for locally advanced NSCLC
  • Other ongoing and planned clinical trials of immune checkpoint inhibitors for patients with nonmetastatic NSCLC

Metastatic NSCLC

  • Clinical trial database supporting the FDA approvals of pembrolizumab and atezolizumab administered as monotherapy and combined with chemotherapy as first- line treatment for metastatic NSCLC
  • Available efficacy and safety data from the Phase III EMPOWER-Lung 1 trial of first-line cemiplimab monotherapy for patients with NSCLC and PD-L1 in ≥50% of tumor cells; recent FDA approval of cemiplimab and current clinical role
  • Phase III clinical trial results (CheckMate 227, CheckMate 9LA) with, patient selection for and integration into practice of first-line nivolumab/ipilimumab with and without chemotherapy
  • Clinical and biologic factors in the selection of anti-PD-1/PD-L1 monotherapy versus combined chemoimmunotherapy versus dual immune checkpoint inhibition for patients with nonsquamous or squamous metastatic NSCLC
  • Efficacy and safety observed with the anti-TIGIT monoclonal antibody tiragolumab in combination with atezolizumab for patients with PD-L1-positive metastatic NSCLC; FDA breakthrough therapy designation and development plans
  • Management of NSCLC that has progressed on first-line anti-PD-1/PD-L1-based therapy; current role of approved agents and regimens (eg, ramucirumab, afatinib, bevacizumab)
  • Biologic rationale for targeting TROP2 in lung cancer; mechanism of action and ongoing investigation of the TROP2-directed antibody-drug conjugate datopotamab deruxtecan for progressive metastatic NSCLC

Genitourinary Cancers | 9:00 AM – 10:00 AM CT (10:00 AM – 11:00 AM ET)

PART I: PROSTATE CANCER (PC)

Nonmetastatic and Hormone-Sensitive Metastatic PC

  • Major efficacy and safety findings with and current clinical role of the oral GnRH antagonist relugolix for men with advanced PC
  • Importance of PSA level, PSA doubling time, disease-free interval and other factors in the decision to initiate androgen deprivation therapy (ADT) in combination with secondary hormonal therapy for PSA-only relapse in men with nonmetastatic castration-resistant PC (nmCRPC)
  • Key efficacy outcomes with enzalutamide, apalutamide or darolutamide for nmCRPC; implications of differing toxicity profiles for therapeutic selection
  • Rationale for the evaluation of secondary hormonal agents for nonmetastatic castration-sensitive PC; ongoing and planned Phase III trials
  • Current role of the PSMA-targeted PET-imaging drug gallium 68 PSMA-11 in the detection of PC metastases
  • Long-term efficacy and safety data with docetaxel, abiraterone, enzalutamide or apalutamide in combination with ADT for metastatic hormone-sensitive PC; clinical and biologic factors in selecting from these agents
  • Design, eligibility criteria and key endpoints of Phase III trials (eg, ARASENS, ARANOTE) assessing darolutamide-based therapy for men with metastatic hormone-sensitive PC

Metastatic Castration-Resistant PC (mCRPC)

  • Key considerations in the selection and sequencing of therapy for patients with mCRPC; impact of earlier use of chemotherapy and secondary hormonal therapy
  • Incidence of BRCA1/2 and other homologous recombination repair abnormalities in patients with PC; indications for and practical implementation of genetic testing
  • Key efficacy and safety data with the approved PARP inhibitors olaparib and rucaparib in men with mCRPC; integration of these agents into management algorithms
  • Ongoing research with PARP inhibitors alone or in combination with secondary hormonal agents for mCRPC
  • Research findings supporting the use of cabazitaxel rather than androgen receptor-targeted treatment for patients with mCRPC
  • Patient selection for radium-223 and optimal integration into mCRPC treatment algorithms
  • Emerging findings from the Phase III VISION study demonstrating improved overall survival and radiographic progression-free survival with 177Lu-PSMA-617 for patients with PSMA-positive mCRPC; potential role in clinical practice
  • Frequency of PTEN loss in mCRPC; key efficacy and safety data with ipatasertib in combination with abiraterone/prednisone for patients with mCRPC and PTEN loss
  • Preliminary findings with and ongoing evaluation of cabozantinib in combination with atezolizumab for mCRPC
  • PART II: RENAL CELL CARCINOMA (RCC) AND UROTHELIAL BLADDER CANCER (UBC)

Renal Cell Carcinoma (RCC)

  • Emerging findings from the KEYNOTE-564 trial demonstrating a disease-free survival advantage with adjuvant pembrolizumab; implications for practice
  • Long-term findings with nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib for treatment-naïve metastatic RCC (mRCC)
  • Major efficacy and safety data from the Phase III CheckMate 9ER trial evaluating nivolumab in combination with cabozantinib for previously untreated mRCC; FDA approval and optimal integration into current first-line treatment algorithms
  • Principal findings from the Phase III KEYNOTE-581/CLEAR trial comparing lenvatinib/pembrolizumab or lenvatinib/everolimus to sunitinib as first-line therapy for mRCC; implications for current and future patient care
  • Available data with and ongoing evaluation of other novel combination strategies (eg, cabozantinib/nivolumab/ipilimumab) for previously untreated advanced RCC
  • Clinical and biologic factors in the selection of therapy for patients who experience relapse on first-line treatment
  • Research database supporting the use of cabozantinib for relapsed/refractory RCC
  • Published data with other tyrosine kinase inhibitors for progressive mRCC (eg, lenvatinib, axitinib, tivozanib) and optimal incorporation into practice
  • Role of rechallenge with alternative checkpoint inhibitor-based approaches for patients who have experienced disease progression on immunotherapy
  • Clinical trial findings (eg, SWOG-S1500/PAPMET) informing the selection of therapy for patients with papillary RCC
  • Belzutifan for von Hippel-Lindau disease-associated RCC: Mechanism of action, available data, FDA priority review status and ongoing evaluation

Urothelial Bladder Cancer (UBC)

  • Selection of patients with high-risk non-muscle-invasive bladder cancer for pembrolizumab therapy
  • Design, eligibility criteria and key efficacy and safety endpoints evaluated in the Phase III CheckMate 274 trial comparing nivolumab to placebo after surgery for patients with high-risk muscle-invasive bladder cancer
  • Disease-free survival advantage with nivolumab in the CheckMate 274 trial and potential role of that agent in clinical practice
  • Ongoing research evaluating anti-PD-1/PD-L1 antibodies for non-muscle-invasive and muscle-invasive bladder cancer
  • Current clinical roles of atezolizumab and pembrolizumab as first-line treatment for metastatic UBC (mUBC)
  • Key efficacy and safety data with maintenance avelumab after front-line chemotherapy for patients with mUBC; appropriate incorporation into clinical care
  • Principal findings with and ongoing trials evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies (eg, chemotherapy, anti-CTLA-4 antibodies) for mUBC
  • Biologic rationale for targeting nectin-4 in UBC; published efficacy and safety findings with enfortumab vedotin for patients with progressive mUBC, including those who have not received platinum-containing chemotherapy
  • Spectrum and frequency of FGFR alterations in patients with mUBC; efficacy and safety data with erdafitinib for patients with mUBC with susceptible FGFR3 or FGFR2 genetic alterations
  • Integration of enfortumab vedotin and erdafitinib into the current treatment paradigm and ongoing research
  • Key findings with and potential clinical role of enfortumab vedotin in combination with pembrolizumab for previously untreated mUBC
  • Biologic rationale for targeting TROP-2 in mUBC; mechanism of action of sacituzumab govitecan
  • Design, eligibility criteria and key efficacy and safety endpoints of the Phase II TROPHY U-01 trial leading to the recent FDA approval of sacituzumab govitecan for progressive mUBC; integration of this agent into clinical management
  • Other promising agents and strategies in UBC (eg, futibatinib, infigratinib, cabozantinib)

PROGRAM BREAK | 10:00 AM – 10:30 AM CT (11:00 AM – 11:30 AM ET)

Chronic Lymphocytic Leukemia and Lymphomas | 10:30 AM – 11:30 AM CT (11:30 AM – 12:30 PM ET)

PART I: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND FOLLICULAR LYMPHOMA (FL)

Management of Chronic Lymphocytic Leukemia (CLL)

  • Data sets informing the use of BTK inhibitor-based therapy for patients with treatment-naïve CLL
  • Design, eligibility criteria and emerging efficacy and safety findings from the Phase III ELEVATE-RR trial comparing acalabrutinib to ibrutinib for previously treated CLL with high-risk features; implications for clinical practice
  • Key data sets informing the optimal utilization of venetoclax for patients with newly diagnosed and relapsed/refractory (R/R) CLL
  • Mechanisms of action, available data and ongoing evaluation of novel noncovalent reversible Bruton tyrosine kinase (BTK) inhibitors for R/R CLL; potential role in CLL management
  • Available efficacy and safety outcomes from studies evaluating novel combinations of BTK and Bcl-2 inhibitors for previously untreated and R/R CLL; ongoing Phase III studies
  • Biologic rationale for, available data with and ongoing evaluation of CD19-directed CAR (chimeric antigen receptor) T-cell therapy for patients with R/R CLL

Management of Follicular Lymphoma (FL)

  • Integration of obinutuzumab into therapeutic algorithms for treatment-naïve and R/R FL
  • Optimal integration of lenalidomide/rituximab into the management of newly diagnosed and R/R FL
  • Similarities and differences among FDA-approved PI3 kinase inhibitors; implications for clinical practice
  • Design, eligibility criteria and key efficacy and safety findings from the Phase III CHRONOS-3 trial evaluating copanlisib in combination with rituximab for patients with R/R FL; implications for clinical practice
  • Available findings from the Phase IIb UNITY-NHL trial evaluating umbralisib for R/R FL in addition to marginal zone lymphoma and small lymphocytic lymphoma; FDA approval of umbralisib
  • Recent FDA approval and current clinical role of tazemetostat for patients with and without EZH2 mutations
  • Available data with and FDA approval of axicabtagene ciloleucel for R/R FL; identification of patients appropriate for treatment with this agent
  • Published efficacy and safety findings with, FDA regenerative medicine advanced therapy designation for and potential clinical role of tisagenlecleucel in FL treatment
  • Biologic rationale for, available data with and ongoing evaluation of bispecific antibody therapy; FDA breakthrough therapy designation for mosunetuzumab in R/R FL

PART II: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), MANTLE CELL LYMPHOMA (MCL) AND HODGKIN LYMPHOMA (HL)

Management of Diffuse Large B-Cell Lymphoma (DLBCL)

  • Long-term data with axicabtagene ciloleucel, tisagenlecleucel or lisocabtagene maraleucel for relapsed/refractory (R/R) DLBCL
  • FDA approval of lisocabtagene maraleucel and optimal integration into patient care
  • Patient identification and appropriate referral for consideration of CAR (chimeric antigen receptor) T-cell therapy
  • Available efficacy and safety data with polatuzumab vedotin in combination with bendamustine/rituximab for R/R DLBCL; incorporation into management algorithms
  • FDA approval of and patient selection for tafasitamab/lenalidomide for R/R DLBCL
  • Selinexor for DLBCL: Patient selection, practical implementation and optimal sequencing
  • Mechanism of action of loncastuximab tesirine and key efficacy and safety findings leading to FDA approval; current role in clinical practice
  • Available data with and ongoing and planned evaluation of novel agents (eg, tafasitamab, selinexor, polatuzumab vedotin) as a component of first-line therapy

Management of Mantle Cell Lymphoma (MCL)

  • Research database supporting the FDA approvals of ibrutinib, acalabrutinib and zanubrutinib for R/R MCL; patient selection for these agents in routine clinical care
  • Activity and safety data with and ongoing Phase III investigations of novel agents (eg, lenalidomide, Bruton tyrosine kinase [BTK] inhibitors) for previously untreated MCL
  • Available data with, current clinical role of and ongoing trials assessing venetoclax alone or combined with other agents, such as BTK inhibitors, for MCL
  • FDA approval of brexucabtagene autoleucel and optimal integration into MCL treatment algorithms
  • Design, eligibility criteria and key efficacy and safety findings from the BRUIN trial evaluating the noncovalent BTK inhibitor pirtobrutinib for B-cell cancers, including MCL

Management of Hodgkin Lymphoma (HL)

  • Role of brentuximab vedotin (BV) in combination with AVD (doxorubicin/vinblastine/dacarbazine) as first-line therapy for advanced classical HL
  • Available data with and current role of BV for older patients with newly diagnosed HL
  • Potential role of BV alone or in combination with immune checkpoint inhibition as a bridge to transplant for patients experiencing disease progression on up-front treatment
  • Optimal management of R/R HL; role of immune checkpoint inhibitors and BV
  • Available activity and safety data with and ongoing evaluation of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic approaches (eg, BV, chemotherapy) for HL

Gastrointestinal Cancers | 11:30 AM – 12:30 PM CT (12:30 PM – 1:30 PM ET)

PART I: COLORECTAL AND GASTROESOPHAGEAL CANCERS

Colorectal and Anal Cancer

  • Indications for molecular testing in patients with metastatic colorectal cancer (mCRC)
  • Available data linking tumor sidedness and response to specific therapeutic interventions for mCRC
  • Integration of encorafenib/cetuximab into therapy for mCRC with a BRAF V600E mutation; available results with and ongoing evaluation of earlier use of BRAF-targeted therapy
  • Incorporation of pembrolizumab, nivolumab and nivolumab/ipilimumab into the treatment of microsatellite instability-high/mismatch repair-deficient mCRC
  • Ongoing investigation of immune checkpoint inhibitors in combination with other systemic approaches (eg, chemotherapy, targeted therapy) for mCRC
  • Available results from the Phase II DESTINY-CRC01 study of trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing mCRC; ongoing evaluation and potential nonresearch role of T-DXd
  • Encouraging antitumor activity observed with selpercatinib in patients with colon cancer and other gastrointestinal tumors with RET fusions
  • Rational incorporation of regorafenib and TAS-102 into treatment algorithms for multiregimen-relapsed mCRC
  • Available data with and potential clinical role of TAS-102 in combination with other systemic agents for metastatic and earlier-stage CRC
  • Mechanism of action of retifanlimab; available data supporting its FDA priority review status for patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who have experienced disease progression or drug intolerance on platinum-based chemotherapy

Gastroesophageal Cancers

  • Available efficacy and safety results from the Phase III CheckMate 649 study comparing first-line nivolumab/chemotherapy to chemotherapy alone for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma; recent FDA approval of up-front nivolumab/chemotherapy and patient selection for this approach
  • Design, eligibility criteria and primary findings from the Phase III KEYNOTE-590 study leading to the recent FDA approval of first-line pembrolizumab/chemotherapy for advanced esophageal cancer
  • Emerging results from the Phase III CheckMate 648 study demonstrating a survival benefit with nivolumab/chemotherapy and with nivolumab/ipilimumab in comparison to chemotherapy alone for unresectable advanced or metastatic esophageal squamous cell carcinoma
  • Primary findings with nivolumab in the adjuvant setting for patients with resected esophageal or GEJ cancer; FDA priority review status and potential role in practice
  • Optimal integration of ramucirumab into clinical algorithms for metastatic gastric/GEJ cancer; ongoing investigation of ramucirumab-containing combination regimens
  • Clinical research supporting the use of TAS-102 for heavily pretreated metastatic gastric/GEJ cancer; patient selection for TAS-102 in routine practice
  • Frequency of HER2 amplification in advanced gastric and GEJ cancer; current management of newly diagnosed and relapsed/refractory HER2-positive disease
  • Available efficacy and safety data with and optimal incorporation into practice of trastuzumab deruxtecan for previously treated HER2-positive metastatic gastric/GEJ cancer
  • Frequency of FGFR2b overexpression in gastroesophageal cancers; mechanism of action of bemarituzumab
  • Available data with, FDA breakthrough therapy designation for and potential clinical role of bemarituzumab for patients with FGFR2b-overexpressing gastric/GEJ cancer

PART II: HEPATOBILIARY AND PANCREATIC CANCERS

Hepatocellular Carcinoma (HCC)

  • Clinical and biologic factors in the selection of first-line treatment for advanced HCC (eg, age, symptomatology, liver function)
  • Key efficacy and safety findings supporting the use of first-line atezolizumab/bevacizumab for unresectable HCC; integration into routine practice
  • Available data with and current clinical role of tyrosine kinase inhibitor monotherapy (eg, sorafenib, lenvatinib) as first-line therapy for unresectable HCC
  • Available data with and ongoing evaluation of other novel combination strategies (eg, lenvatinib/pembrolizumab, lenvatinib/nivolumab, cabozantinib/atezolizumab, cabozantinib/nivolumab/ipilimumab) for advanced HCC
  • Key factors in the selection and sequencing of approved regimens for patients whose disease has progressed on first-line therapy
  • Long-term outcomes with approved anti-angiogenic agents (eg, regorafenib, cabozantinib, ramucirumab) for patients with progressive HCC
  • Published efficacy and safety data with the use of anti-PD-1/PD-L1 antibodies alone or in combination with anti-CTLA antibodies for relapsed HCC

Cholangiocarcinoma

  • Spectrum, frequency and clinical implications of targetable molecular alterations in patients with advanced cholangiocarcinoma
  • Efficacy and safety data contributing to the FDA approval of the selective FGFR inhibitor pemigatinib for patients with pretreated cholangiocarcinoma with an FGFR2 translocation; ongoing Phase III evaluation for treatment-naïve disease
  • Efficacy and safety outcomes with futibatinib for intrahepatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement; FDA breakthrough therapy designation for futibatinib and ongoing evaluation
  • Available evidence with other FGFR-targeted agents (eg, infigratinib, erdafitinib) in advanced cholangiocarcinoma; ongoing trials evaluating FGFR inhibition for patients with treatment-naïve or progressive disease
  • Outcomes from the Phase III ClarIDHy study evaluating the IDH1 inhibitor ivosidenib for patients with previously treated cholangiocarcinoma with an IDH1 mutation; implications for practice and research

Pancreatic Cancer

  • Available clinical trial results evaluating the utility of contemporary cytotoxic regimens as preoperative therapy for patients with resectable or borderline-resectable pancreatic adenocarcinoma (PAD)
  • Selection of adjuvant systemic therapy for patients with resected PAD
  • Optimal selection of first- and later-line treatment for metastatic PAD; importance of patient age, comorbidities and prior therapy
  • Early front-line activity data with NALIRIFOX, the combination of nanoliposomal irinotecan (nal-IRI), 5-FU/leucovorin and oxaliplatin, in patients with metastatic PAD
  • Nal-IRI for relapsed metastatic PAD: Patient selection and practical integration into practice
  • Incidence of BRCA1/2 mutations and other DNA damage repair abnormalities in patients with PAD; guideline-endorsed algorithms for genetic testing
  • Key efficacy and safety findings with and optimal integration of olaparib as maintenance therapy after first-line chemotherapy for patients with metastatic PAD and a germline BRCA mutation
  • Other novel agents and strategies under investigation for PAD

PROGRAM BREAK | 12:30 PM – 1:00 PM CT (1:30 PM – 2:00 PM ET)

Gynecologic Cancers | 1:00 PM – 2:00 PM CT (2:00 PM – 3:00 PM ET)

PART I: OVARIAN CANCER (OC)

Role of PARP Inhibitors in Ovarian Cancer (OC) Management

  • Clinical and biologic factors in the selection and sequencing of therapy for patients with newly diagnosed advanced OC; indications for first-line maintenance therapy
  • Outcomes with PARP inhibitor maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC and a BRCA mutation
  • Practical considerations with the use of PARP inhibitors as maintenance therapy for newly diagnosed OC
  • Available efficacy and safety data with maintenance olaparib/bevacizumab for patients with advanced OC who respond to first-line platinum-based chemotherapy and bevacizumab
  • Incidence of homologous recombination deficiency (HRD) in patients with advanced OC; indications and optimal platforms for HRD assessment
  • Available data with and clinical use of PARP inhibitors as maintenance therapy for HRD-positive advanced OC
  • Optimal management of newly diagnosed BRCA-negative, HRD-negative OC; current role of maintenance therapy with PARP inhibitors
  • Indications for PARP inhibitors in patients with platinum-sensitive and platinum-refractory recurrent OC

Ongoing Investigation of Novel Approaches for Ovarian Cancer (OC)

  • Published research with anti-PD-1/PD-L1 antibodies alone or in combination with chemotherapy or chemobiologic therapy for newly diagnosed and recurrent advanced OC
  • Biologic rationale for combining PARP inhibitors with anti-PD-1/PD-L1 antibodies and/or bevacizumab; available efficacy and safety findings with various combinations
  • Ongoing Phase III trials evaluating immune checkpoint inhibitors in combination with PARP inhibitors for advanced OC
  • Scientific rationale for targeting folate receptor alpha and available data with mirvetuximab soravtansine alone or in combination with other anticancer therapies (eg, bevacizumab)
  • Spectrum, frequency and severity of toxicities with mirvetuximab soravtansine
  • Ongoing evaluation of mirvetuximab soravtansine for advanced OC and potential role in clinical management
  • Other promising novel agents and strategies under investigation

PART II: CERVICAL AND ENDOMETRIAL CANCERS

Management of Cervical Cancer (CC)

  • Current management of metastatic CC; optimal selection and sequencing of available therapies
  • FDA approval and current indications for pembrolizumab; integration into the care of patients with metastatic disease
  • Design, eligibility criteria and key efficacy and safety endpoints of the Phase III EMPOWER Cervical-1 trial evaluating cemiplimab versus investigator’s choice of chemotherapy for platinum-refractory CC
  • Emerging results from the EMPOWER Cervical-1 trial demonstrating an overall survival advantage with cemiplimab; potential application in clinical practice
  • Mechanism of action, available research findings and potential clinical role of balstilimab for CC
  • Scientific justification for, available data with and ongoing evaluation of anti-PD-1/PD-L1/anti-CTLA-4 combinations (eg, balstilimab and zalifrelimab) for advanced CC
  • Published and ongoing research with anti-PD-1/PD-L1 antibodies in combination with chemotherapy or chemoradiation therapy for the management of localized and metastatic CC
  • Design, eligibility criteria and key efficacy and safety findings from the pivotal Phase II innovaTV 204 trial evaluating tisotumab vedotin monotherapy for recurrent or metastatic CC
  • Potential role of tisotumab vedotin in clinical practice
  • Mechanisms of action and ongoing evaluation of other investigational agents and strategies with promising activity in advanced CC

Management of Endometrial Cancer (EC)

  • Key factors in the selection and sequencing of therapy for patients with advanced EC
  • Incidence of high microsatellite instability (MSI) or DNA mismatch repair (MMR) deficiency in patients with advanced EC; current indications for testing
  • Available efficacy and safety outcomes with commercially available anti-PD-1/PD-L1 antibodies for patients with MSI-high/MMR-deficient (dMMR) advanced EC; clinical role of pembrolizumab
  • Mechanism of action of dostarlimab; available safety and efficacy data with dostarlimab for patients with MSI-high/dMMR or microsatellite stable (MSS) tumors
  • FDA approval of dostarlimab for patients with dMMR EC and disease progression on or after a platinum-containing regimen; integration into practice
  • Biologic rationale for combining immune checkpoint inhibitors with chemotherapy for EC; current Phase III trials for patients with recurrent or primary advanced disease
  • Key efficacy and safety findings from early-stage trials assessing lenvatinib in combination with pembrolizumab for patients with relapsed/refractory EC
  • FDA approval and current clinical utilization of lenvatinib/pembrolizumab for patients with advanced EC that is not MSI high or dMMR who have experienced disease progression after systemic therapy but who are not candidates for curative surgery or radiation therapy
  • Efficacy and safety findings from the Phase III KEYNOTE-775 trial evaluating lenvatinib/pembrolizumab versus standard chemotherapy for recurrent EC; implications for the management of MSS and MSI-high/dMMR disease
  • Other promising agents and strategies under investigation for EC

Breast Cancer | 2:00 PM – 3:00 PM CT (3:00 PM – 4:00 PM ET)

PART I: EARLY-STAGE BREAST CANCER

HER2-Positive Disease

  • Key clinical factors in the decision to administer neoadjuvant treatment to patients with HER2-positive localized breast cancer
  • Clinical implications of the FDA approval of adjuvant T-DM1 for patients with residual disease after neoadjuvant therapy
  • Long-term efficacy and safety findings with pertuzumab as a component of adjuvant treatment for HER2-positive localized breast cancer
  • Patient selection for and clinical factors guiding the use of neratinib as extended-adjuvant therapy; improvement in rates of CNS recurrence after long-term follow-up of the Phase III ExteNET study

ER-Positive Disease

  • Design, eligibility criteria and major clinical findings from the Phase III RxPONDER trial evaluating chemotherapy for patients with ER-positive, HER2-negative early breast cancer with 1 to 3 positive lymph nodes and a 21-gene Recurrence Score® of ≤25
  • Benefit with chemotherapy for premenopausal versus postmenopausal patients in the RxPONDER trial; implications for practice
  • Other recent clinical trial findings (eg, ADAPT) informing the use of genomic assays to guide neoadjuvant and adjuvant treatment decision-making
  • Improvement in invasive disease-free survival with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative breast cancer at high risk for recurrence in the Phase III monarchE trial
  • Spectrum, frequency and severity of toxicities reported with abemaciclib in the monarchE trial; rates of treatment discontinuation after less than 2 years
  • Other ongoing and planned studies evaluating CDK4/6 inhibitors as neoadjuvant or adjuvant therapy

Triple-Negative Disease

  • Design, eligibility criteria and primary and secondary endpoints of the Phase III OlympiA trial assessing adjuvant olaparib for patients with germline BRCA1/2 mutations and high-risk HER2-negative breast cancer who have completed definitive local treatment and adjuvant or neoadjuvant chemotherapy
  • Emerging results from the interim analysis of the OlympiA trial demonstrating superior invasive disease-free survival with olaparib; current and potential role of adjuvant olaparib
  • Major efficacy and safety findings from Phase III studies (eg, KEYNOTE-522, IMpassion031) evaluating the addition of anti-PD-1/PD-L1 antibodies to chemotherapy as neoadjuvant treatment for early-stage triple-negative breast cancer; current nonresearch role of neoadjuvant checkpoint inhibition

PART II: METASTATIC BREAST CANCER (mBC)

HER2-Positive Disease

  • Clinical factors (eg, prior HER2-directed therapy, symptomatology, disease-free interval, sites of metastases) in the selection of therapy for patients with HER2-positive mBC
  • Available efficacy and safety data from the pivotal Phase II HER2CLIMB trial of tucatinib in combination with trastuzumab/capecitabine for patients with HER2-positive mBC, including those with brain metastases
  • Outcomes from the Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan for previously treated advanced HER2-positive BC
  • Available data with and current role of neratinib/capecitabine for patients with HER2-positive mBC
  • Mechanism of action of margetuximab; key efficacy findings with margetuximab/chemotherapy compared to trastuzumab/chemotherapy for multiregimen-relapsed HER2-positive mBC
  • Optimal integration of tucatinib/trastuzumab/capecitabine, trastuzumab deruxtecan, neratinib/capecitabine and margetuximab/chemotherapy into practice
  • Comparative adverse-event profiles of the newer anti-HER2 therapies; strategies to monitor for, prevent and manage complications

ER-Positive Disease

  • Long-term follow-up data with a CDK4/6 inhibitor and an endocrine partner for ER-positive mBC; factors in the selection of specific agents
  • Incidence, monitoring and management of commonly occurring class and agent-specific toxicities associated with CDK4/6 inhibition
  • Published research findings with alpelisib/fulvestrant for patients with ER-positive mBC with a PIK3CA mutation
  • Spectrum, frequency and severity of alpelisib-related toxicities; optimal prevention and management strategies (eg, prophylactic antihistamines)
  • Early clinical research findings with and ongoing Phase III evaluation of sacituzumab govitecan for refractory hormone receptor-positive mBC
  • Other novel agents and strategies under investigation for ER-positive mBC (eg, patritumab deruxtecan, capivasertib, SERDs [selective estrogen receptor degraders], FGFR inhibitors)

Triple-Negative Disease

  • Key efficacy and safety findings from the Phase III KEYNOTE-355 trial evaluating the addition of pembrolizumab to chemotherapy for previously untreated metastatic triple-negative breast cancer (TNBC); effect of chemotherapy partner on outcomes
  • FDA approvals of atezolizumab/nab paclitaxel and pembrolizumab/chemotherapy for PD-L1-positive metastatic TNBC; integration into practice
  • Key clinical research findings guiding the use of PARP inhibitors for patients with mBC
  • Key efficacy and safety findings from the Phase III ASCENT trial comparing sacituzumab govitecan to physician’s choice of chemotherapy for relapsed/refractory TNBC
  • FDA approval of sacituzumab govitecan for metastatic TNBC and integration into clinical practice
  • Other novel agents under investigation for TNBC (eg, trastuzumab deruxtecan, ladiratuzumab vedotin, datopotamab deruxtecan)

PROGRAM ADJOURNS

Target Audience
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.

Learning Objectives

LUNG CANCER

  • Evaluate available and emerging data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based neoadjuvant or adjuvant therapy in patients with nonmetastatic non-small cell lung cancer (NSCLC).
  • Appraise the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and appropriately integrate this strategy into routine clinical practice.
  • Acknowledge the FDA approval of adjuvant osimertinib for early-stage NSCLC with an EGFR mutation, and identify patients for whom treatment with this novel approach would be warranted.
  • Review published research data documenting the safety and efficacy of EGFR tyrosine kinase inhibitors alone or in combination with other systemic approaches for metastatic NSCLC with an EGFR tumor mutation, and apply this information in the care of appropriately selected patients.
  • Assess the efficacy and safety of commercially available ALK inhibitors for patients with metastatic NSCLC with an ALK rearrangement, and apply this understanding to select and sequence these drugs as first- and later-line therapy.
  • Recall other oncogenic pathways (ie, ROS1, RET, MET, HER2, KRAS) mediating the patho- genesis of tumors in unique patient subsets, and refer to published and emerging data with commercially available and experimental agents exploiting these targets.
  • Review recent advances in the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or chemobiologic therapy for metastatic NSCLC, and discern how these approaches can be optimally employed in the management of this disease.
  • Recognize the recent FDA approvals of nivolumab in combination with ipilimumab with and without chemotherapy as first-line treatment for patients with metastatic NSCLC, and appropriately incorporate these novel regimens into treatment algorithms.
  • Appreciate available clinical trial findings informing the use of immune checkpoint inhibitors in combination with platinum-based chemotherapy for patients with previously untreated extensive-stage small cell lung cancer (SCLC).
  • Design an optimal approach to the clinical care of patients with progressive SCLC, considering the implications of prior therapeutic exposure, symptomatology and other factors.

GENITOURINARY CANCERS

  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the recommendation of nonresearch treatment options for patients.
  • Explore available data with cytotoxic and secondary hormonal therapy for metastatic hormone-sensitive prostate cancer to design effective treatment plans for patients.
  • Apply clinical research findings in the determination of best-practice selection and sequencing of available treatment modalities for patients with metastatic CRPC.
  • Evaluate the recent FDA approvals of olaparib and rucaparib for patients with metastatic CRPC, and optimally incorporate these agents into clinical management algorithms.
  • Consider published and emerging research, clinical investigator perspectives and available guideline recommendations to individualize first-line therapy for patients with advanced renal cell carcinoma (RCC).
  • Develop a rational approach to the sequencing of systemic therapies for patients with advanced RCC who experience disease progression on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors and immunotherapeutic agents.
  • Recognize available clinical trial evidence with immune checkpoint inhibitors for nonmetastatic urothelial bladder carcinoma (UBC) to determine the current and potential utility of this strategy in clinical practice.
  • Review available clinical trial data with anti-PD-1/PD-L1 antibodies for patients with newly diagnosed or relapsed/refractory metastatic UBC in order to optimally incorporate these agents into management algorithms.
  • Recall the mechanisms of action of and pivotal clinical trial findings with enfortumab vedotin, erdafitinib and sacituzumab govitecan for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with these novel compounds would be appropriate.
  • Appraise available research data and ongoing clinical trials evaluating novel agents and strategies for prostate cancer, RCC and UBC, and counsel appropriately selected patients about participation in active research protocols.

CHRONIC LYMPHOCYTIC LEUKEMIA AND LYMPHOMAS

  • Individualize the selection and sequencing of systemic therapy for patients with newly diagnosed or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), considering clinical presentation, age, performance status (PS), biomarker profile and coexisting medical conditions.
  • Understand published research data informing the selection, sequencing and combining of available therapeutic agents in the nonresearch care of patients with previously untreated or R/R follicular lymphoma (FL).
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of those agents in clinical practice.
  • Consider patient age, PS and other clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
  • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma.
  • Assess available clinical trial findings informing the use of CD19-directed CAR T-cell therapy for R/R DLBCL, MCL and FL, and counsel appropriately selected patients regarding the potential benefits of this strategy.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for CLL, FL, MCL, DLBCL and Hodgkin lymphoma in order to support quality of life and continuation of treatment.
  • Recall new data with agents and strategies currently under investigation for CLL and various lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

GASTROINTESTINAL CANCERS

  • Develop a long-term care plan for patients diagnosed with metastatic colorectal cancer, considering their biomarker profile, tumor location, exposure to prior systemic therapy, symptomatology, performance status (PS) and personal goals of treatment.
  • Use HER2 status, PD-L1 combined positive score and other clinical and biologic factors to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastric, gastroesophageal junction and esophageal cancers.
  • Consider age, PS, liver function and other clinical factors in the selection of first- and later-line therapy for patients with unresectable or metastatic hepatocellular carcinoma.
  • Recall clinical trial data with approved and investigational systemic interventions for patients with localized, locally advanced or metastatic pancreatic adenocarcinoma, and establish an evidence-based approach to selecting therapy.
  • Appreciate the molecular heterogeneity of cholangiocarcinomas, and apply available clinical research findings in the formulation of individualized therapeutic approaches for patients with unresectable and metastatic disease.
  • Appraise available and emerging data with investigational agents currently in clinical testing for gastrointestinal cancers, and where applicable, refer eligible patients for trial participation.

GYNECOLOGIC CANCERS

  • Consider the FDA approval of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer (OC) harboring a deleterious or suspected deleterious BRCA germline or somatic mutation, and counsel appropriate individuals regarding personalized treatment recommendations.
  • Recognize the recent FDA approval of niraparib as maintenance therapy in the first-line setting for patients with advanced OC with or without BRCA mutations, and discern for which individuals treatment with this agent may be appropriate.
  • Evaluate available clinical trial data leading to the recent FDA approval of olaparib/bevacizumab as maintenance therapy for patients with newly diagnosed OC responding after first-line platinum-taxane chemotherapy with bevacizumab to determine the role of this novel strategy in practice.
  • Recall the recent FDA approval of the anti-PD-1 antibody dostarlimab for recurrent or advanced mismatch repair-deficient endometrial cancer (EC), and identify patients for whom treatment with this novel agent should be considered.
  • Consider the FDA approval of pembrolizumab in combination with lenvatinib for patients with advanced EC that is not microsatellite instability high or mismatch repair deficient who experience disease progression after prior systemic therapy, and apply this information to optimally integrate this novel regimen into clinical management algorithms.
  • Appraise available and emerging research findings supporting the use of immune checkpoint inhibitors for progressive metastatic cervical cancer (CC), and identify patients appropriate for research-protocol or nonresearch treatment with these agents.
  • Recognize the incidence of tissue factor expression in patients with CC and other gynecologic cancers, and consider emerging pivotal research findings with and the potential role of tisotumab vedotin in the treatment of recurrent CC.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for gynecologic cancers, and counsel appropriate patients about availability and participation

BREAST CANCER

  • Evaluate published research data guiding the selection and duration of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer, incorporating existing and recently approved anti-HER2 therapies.
  • Recognize common and rare side effects associated with novel anti-HER2 agents, and use this information to develop supportive management plans for patients with HER2-positive breast cancer undergoing treatment.
  • Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize the use of adjuvant systemic therapy for newly diagnosed ER-positive breast cancer.
  • Consider available and emerging clinical trial findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the potential role of these agents as neoadjuvant or adjuvant treatment.
  • Individualize the selection and sequence of systemic therapy for patients with ER-positive metastatic breast cancer, considering age, menopausal status, prior treatment course, PIK3CA mutation status, comorbidities, symptomatology and extent and sites of disease.
  • Appreciate emerging Phase III data documenting the efficacy of olaparib as adjuvant therapy for patients with high-risk HER2-negative early breast cancer with BRCA mutations, and consider the potential role of this strategy in clinical practice.
  • Review published research data supporting the benefit of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for patients with newly diagnosed PD-L1-positive metastatic triple-negative breast cancer (TNBC), and use this information to make appropriate treatment recommendations.
  • Evaluate published research findings guiding the selection and sequencing of available therapeutic agents for patients with PD-L1-negative TNBC or those who experience disease progression on front-line chemoimmunotherapy.
  • Appraise published efficacy and safety data with PARP inhibitors for patients with metastatic breast cancer harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
  • Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for localized and metastatic breast cancer.

Accreditation Statements
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

NCPD Credit Designation Statements
This educational activity for 6 contact hours is provided by Research To Practice.

This activity is awarded 6 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must return a completed Educational Assessment and Credit Form for the modules they attend. The credit form links will be emailed to participants within 5 business days of the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice, ACCME or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

Research To Practice CME/NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.